Table 2.

Tumor response to erlotinib according to clinical and molecular variables

Response rate
Disease control rate
n (%)Pn (%)P
Overall rate29/120 (24.2)68/120 (56.7)
Age (n = 120)
    <6017/53 (32.1)0.16533/53 (62.3)0.470
    ≥6014/67 (20.9)35/67 (52.2)
Sex (n = 120)
    Male12/76 (15.8)0.00131/76 (40.8)0.001
    Female19/44 (43.2)37/44 (84.1)
Stage (n = 120)
    IIIB5/16 (31.3)0.59510/16 (62.5)0.610
    IV26/104 (25.0)58/104 (55.8)
Histology (n = 120)
    Adenocarcinoma26/74 (35.1)0.00347/74 (63.5)0.055
    Others5/46 (10.9)21/46 (45.7)
ECOG performance status (n = 120)
    0-129/107 (27.1)0.36261/107 (57.0)0.830
    2-32/13 (15.4)7/13 (53.8)
Smoking (n = 120)
    Never smoker17/48 (35.4)0.04136/48 (75.0)0.003
    Smoker14/72 (19.4)32/72 (44.4)
Erlotinib (n = 120)
    First line6/19 (31.6)0.53313/19 (68.4)0.260
    ≥Second line25/101 (24.8)55/101 (54.5)
Skin rash (n = 120)
    Yes28/93 (30.1)0.04761/93 (65.6)0.001
    No3/27 (11.1)7/27 (25.9)
EGFR mutation* (n = 92)
    Wild-type11/68 (16.2)<0.00135/68 (51.5)0.045
    Mutation (exon 18, 19, or 21)14/24 (58.3)18/24 (75.0)
EGFR amplification (n = 88)
    Normal9/52 (17.3)0.01224/52 (46.2)0.015
    Amplification15/36 (41.7)26/36 (72.2)
EGFR expression (n = 75)
    Normal7/21 (33.3)0.41610/21 (47.6)0.536
    Overexpression13/54 (24.1)30/54 (55.6)
  • * Exon 18, 19, or 21.